Boston Commerce

Why is Boston Commerce Limited falling/rising?

As of 30-Jun, Boston Commerce Limited's stock price is falling, currently at 5.53, reflecting a decline of -4.82%. The stock has significantly underperformed the Sensex, with substantial declines over various time frames and decreased investor participation contributing to its downward trend.

As of 30-Jun, Boston Commerce Limited's stock price is falling, currently at 5.53, which reflects a change of -0.28 or -4.82%. The stock has underperformed significantly compared to the benchmark Sensex, with a 1-week decline of -7.68% while the Sensex increased by +0.36%. Over the past month, the stock has dropped by -25.77%, contrasting with a +2.28% rise in the Sensex. Year-to-date, Boston Commerce has seen a decrease of -23.93%, compared to a -10.26% decline in the Sensex.<BR><BR>Today's performance indicates that the stock has underperformed its sector by -6.67%. Additionally, the stock has exhibited erratic trading patterns, not trading on one day out of the last 20 days. It is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a consistent downward trend. Furthermore, there has been a significant drop in investor participation, with delivery volume on June 29 falling by -99.42% against the 5-day average. This lack of trading activity and declining investor interest contribute to the stock's downward movement. Overall, these factors collectively explain why Boston Commerce Limited's stock price is currently falling.

Which are the latest news on Boston Commerce?

What does Boston Commerce do?

Boston Commerce Limited trades medical equipment and testing kits in the healthcare services industry. It was incorporated in 1995 and currently has a market cap of INR 5 Cr, with a recent net profit of -1 Cr for the quarter ending March 2026.

Overview: <BR>Boston Commerce Limited is engaged in the trading of medical equipment and testing kits within the healthcare services industry and operates as a micro-cap company.<BR><BR>History: <BR>Boston Commerce Limited was incorporated on April 17, 1995. Initially, the company was involved in share broking, investment, and trading in shares and derivatives. Currently, it focuses on trading goods such as medical equipment and testing instruments. The latest quarterly results reported a net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 5 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>Industry: Healthcare Services <BR>Market cap: INR 5 Cr (Micro Cap) <BR>Industry P/E: 92 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.00 <BR>Return on Equity: 0.00% <BR>Price to Book: 0.00<BR><BR>Contact Details: <BR>Address: 17/B 4th Floor Mirzapur, Sandesh Commercial Complex Ahmedabad Gujarat : 380001 <BR>Tel: 91-9098433517 <BR>Email: bostonsystem@yahoo.com <BR>Website: http://www.bostonbiosystemltd.com

How big is Boston Commerce?

As of 10th June, Boston Commerce Limited has a market capitalization of 5.00 Cr and reported Net Sales of 0.48 Cr with a Net Profit loss of 0.58 Cr over the latest 4 quarters. Shareholder's Funds are 5.90 Cr and Total Assets are 14.90 Cr.

As of 10th June, Boston Commerce Limited has a market capitalization of 5.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Boston Commerce reported Net Sales of 0.48 Cr. However, it experienced a loss of 0.58 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025. Shareholder's Funds are reported at 5.90 Cr, while Total Assets amount to 14.90 Cr.

Who are in the management team of Boston Commerce?

The management team of Boston Commerce includes Ramesh Kumar G Dave (Managing Director), Sanjay Sodani, Kushal Rathore, Amit Ashwinbhai Pandya, Ankit Sanjay Disoja, Narendra Mathurbhai Gandhi (all Non Executive Directors), and Seema Baghel (Additional Independent Director).

The management team of Boston Commerce includes the following members:<BR><BR>1. Ramesh Kumar G Dave - Managing Director<BR>2. Sanjay Sodani - Non Executive Director<BR>3. Kushal Rathore - Non Executive Independent Director<BR>4. Amit Ashwinbhai Pandya - Non Executive Director<BR>5. Ankit Sanjay Disoja - Non Executive Director<BR>6. Narendra Mathurbhai Gandhi - Non Executive Director<BR>7. Seema Baghel - Additional Director (Independent)<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

Who are the peers of the Boston Commerce?

Boston Commerce's peers include Adeshwar Meditex, Transgene Biotek, Family Care, Vanta Bioscience, Dr Lalchand. Lab, Clinitech Lab, Looks Health, Dhanvantri Jeev., Ashram Online, and Gian Lifecare. Family Care stands out with excellent management and capital structure, while Looks Health has the highest 1-year return at 85.17%, and Gian Lifecare has the lowest at -62.42%.

Peers: The peers of Boston Commerce are Adeshwar Meditex, Transgene Biotek, Family Care, Vanta Bioscience, Dr Lalchand. Lab, Clinitech Lab, Looks Health, Dhanvantri Jeev., Ashram Online, Gian Lifecare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Family Care, while Average management risk is found at Family Care, and the rest have Below Average management risk, including Adeshwar Meditex, Vanta Bioscience, Dr Lalchand. Lab, Clinitech Lab, Dhanvantri Jeev., and Gian Lifecare. Growth ratings show that Family Care has Good growth, while Average growth is seen at Family Care, and the rest have Below Average growth, including Adeshwar Meditex, Vanta Bioscience, Dr Lalchand. Lab, Clinitech Lab, Dhanvantri Jeev., and Gian Lifecare. For Capital Structure, Family Care stands out with Excellent capital structure, while Good capital structure is noted at Dr Lalchand. Lab, Clinitech Lab, and Dhanvantri Jeev., while the rest have Average or Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Looks Health at 85.17%, while Gian Lifecare has the lowest at -62.42%. Boston Commerce's 1-year return of -10.61% is better than Gian Lifecare's but worse than Looks Health's. Additionally, the peers with negative six-month returns include Adeshwar Meditex, Vanta Bioscience, Dr Lalchand. Lab, Dhanvantri Jeev., Gian Lifecare, and Ashram Online.

When is the next results date for Boston Commerce Limited?

The next results date for Boston Commerce Limited is 30 May 2026.

The next results date for Boston Commerce Limited is scheduled for 30 May 2026.

How has been the historical performance of Boston Bio?

Boston Bio has experienced significant financial decline, with net sales dropping from 1.50 Cr in March 2016 to 0.19 Cr in March 2025, alongside increasing losses and negative cash flow. The company reported an operating profit of -0.55 Cr in March 2025, reflecting ongoing operational challenges.

Answer:<BR>The historical performance of Boston Bio shows significant fluctuations in its financial metrics over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Boston Bio's net sales have seen a notable decline from 1.50 Cr in March 2016 to just 0.19 Cr in March 2025, with a complete absence of sales in the intervening years of March 2017, March 2018, and March 2024. The total operating income followed a similar trend, peaking at 1.50 Cr in March 2016 and dropping to 0.19 Cr in March 2025. The company has consistently reported no raw material costs or purchase of finished goods, indicating a lack of production activity. Total expenditure, however, increased to 0.74 Cr in March 2025, up from 0.14 Cr in March 2024, primarily driven by other expenses. This led to an operating profit (PBDIT) of -0.55 Cr in March 2025, reflecting a negative operating profit margin of -289.47%. The profit before tax and profit after tax also mirrored this negative trend, both standing at -0.55 Cr in March 2025. The earnings per share (EPS) further illustrate the company's struggles, with an EPS of -0.79 in March 2025 compared to -0.20 in March 2024. Cash flow from operating activities was -4.00 Cr in March 2025, indicating a significant cash outflow, while cash flow from financing activities was positive at 4.00 Cr, suggesting reliance on external financing to manage operations. Overall, Boston Bio's financial performance has been characterized by declining sales, increasing losses, and negative cash flow, highlighting ongoing challenges in its business operations.

Who are the top shareholders of the Boston Bio?

The top shareholders of Boston Bio are Jyotshna Jagdishchandra Shah with 2.14% and Mayank Doshi with 2.6%. Individual investors hold a significant 85.33% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Boston Bio include Jyotshna Jagdishchandra Shah, who holds the highest promoter stake at 2.14%. The highest public shareholder is Mayank Doshi, with a holding of 2.6%. Additionally, individual investors collectively own a significant portion of the company, accounting for 85.33% of the shares. There are no institutional holdings or pledged promoter holdings reported.

What is the technical trend for Boston Bio?

As of June 5, 2025, Boston Bio's trend has shifted to bearish, supported by weekly MACD and Bollinger Bands, while daily moving averages confirm this trend, despite mixed signals from the KST and unclear indications from RSI and Dow Theory.

As of 5 June 2025, the technical trend for Boston Bio has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the weekly MACD and Bollinger Bands, both signaling bearish conditions. The daily moving averages also confirm a bearish trend. The KST shows a mixed signal with a bearish weekly reading and a bullish monthly reading, indicating some divergence in longer-term momentum. Overall, the lack of clear signals from the RSI and Dow Theory suggests a continuation of the bearish trend without any immediate reversal in sight.

Has Boston Bio declared dividend?

No Dividend History Available